"Guggenheim analyst Seamus Fernandez raised his firm's price target on AstraZeneca to 16,500 GBp from 16,000 GBp, maintaining a Buy rating after updating the firm's model ahead of Q1 earnings."
"The oncology segment generated $25.618 billion in FY2025 revenue, up 17% CER, anchored by Tagrisso at $7.254 billion and Enhertu at $2.775 billion, up 40% CER."
"AstraZeneca recorded 16 positive Phase 3 readouts and 43 regulatory approvals in 2025, with 20+ Phase 3 trial readouts expected in 2026, indicating a robust pipeline."
AstraZeneca PLC shares rose 31.43% over the past year, with a year-to-date gain of 6.02%. The stock recently pulled back nearly 5% from a 52-week high. Wall Street analysts have a consensus price target of $208.54, while Guggenheim's Seamus Fernandez raised his target to 16,500 GBp, maintaining a Buy rating. The company's oncology segment generated significant revenue, and AstraZeneca recorded numerous positive Phase 3 readouts and regulatory approvals, indicating strong future growth potential.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]